drugset / Trial / NCT05231746

A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

NCT05231746

Phase 1 Completed 47 enrolled STCube, Inc.
NaSequentialOpen-labelTreatment

Summary

The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.

Timeline

Start
2022-04-18
Primary completion
2024-02-29
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelmastobart Monoclonal antibody Intravenous

Indications